Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted hepatitis C lookback: Quebec, Canada.

A Long1, G Spurll, H Demers

  • 1Canadian Red Cross Society, Blood Services, Transfusion Center of Quebec, Montreal.

Transfusion
|February 26, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic risk-targeted islet autoantibody screening for presymptomatic type 1 diabetes in adults.

The lancet. Diabetes & endocrinology·2025
Same author

Multi-criteria analysis of strategies towards sustainable recycling of phosphorus from sewage sludge in Austria.

Journal of environmental management·2024
Same author

Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).

Journal of neuro-oncology·2024
Same author

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

Journal of neuro-oncology·2024
Same author

A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

Journal of neuro-oncology·2023
Same author

Facile formulation and fabrication of the cathode using a self-lithiated carbon for all-solid-state batteries.

Scientific reports·2020
Same journal

Investigation of the preanalytical stability of blood donor samples.

Transfusion·2026
Same journal

The need for dried plasma-Still a national issue: Where are we and recommendations.

Transfusion·2026
Same journal

Spray dried plasma manufactured from apheresis and whole blood derived plasma.

Transfusion·2026
Same journal

Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

Transfusion·2026
Same journal

AABB survey on directed blood donation practices.

Transfusion·2026
Same journal

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
See all related articles

Canadian blood donations are screened for hepatitis C virus (HCV). Targeted HCV lookback studies identified 101 recipients unaware of their infection, highlighting the importance of donor screening and recipient notification.

Area of Science:

  • Transfusion Medicine
  • Hepatology
  • Public Health

Background:

  • Canadian blood donations have been screened for hepatitis C virus (HCV) antibodies since March 1990.
  • Targeted HCV lookback studies were initiated in February 1995 due to the potential for chronic, asymptomatic HCV infection.

Purpose of the Study:

  • To assess the effectiveness and outcomes of targeted hepatitis C virus (HCV) lookback studies in Quebec.
  • To evaluate the resources and costs associated with implementing HCV lookback programs in hospital settings.

Main Methods:

  • Analysis of 3,196 blood components issued from anti-HCV-positive donors between March 1990 and March 1997.
  • Survey of 109 hospitals to determine lookback procedures and resource allocation.
  • Development of a standard operating procedure for lookbacks at the Royal Victoria Hospital (RVH) and cost-outcome analysis.

Related Experiment Videos

Main Results:

  • Information was received for 73% of components; 353 patients were tested.
  • Of those tested, 215 (61%) were anti-HCV positive. At RVH, 9 previously undiagnosed seropositive recipients were identified from 182 components.
  • The cost per newly diagnosed HCV case ranged from $2727 (Quebec Center) to $6014 (RVH).

Conclusions:

  • Targeted lookback studies on 3,196 components in Quebec identified 101 recipients unaware of their HCV status.
  • The study underscores the value of lookback programs in identifying undiagnosed HCV infections among transfusion recipients.